Joshua J Hon

Mr. Joshua J Hon

Faculty of Medicine, Imperial College London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
Joshua J HonJoshua J Hon
Joshua J Hon
GCGerald Carr-White
Gerald Carr-White

11 April 2025 in Translational Stroke Research
Verified
Journal Article
Open access
PDF file
YAYash Akkara
Yash Akkara
Joshua J HonJoshua J Hon
Joshua J Hon
MAMahathir Ahmed
Mahathir Ahmed
BMBasel Musmar
Basel Musmar
JRJoanna Roy
Joanna Roy
PJPascal Jabbour
Pascal Jabbour
Introduction: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are gold-standard treatments of carotid artery stenosis. This study aims to identify the cost-effectiveness of CEA vs CAS. Methods: Studies were screened through PubMed, MEDLINE, and Embase using PRISMA guidelines, and required ≥ 20 participants who were ≥ 16 years, alongside costs at 1-year postoperatively. The Shapiro–Wilk test, independent sample t-tests, ANOVA, and Spearman’s R were used, with costs adjusted to 2024. A random-effects model was used to compare cost-effectiveness. Bias assessment was according to the Cochrane Risk of Bias 2.0 tool and the Newcastle–Ottawa Scale. Results: 7 studies were included, with a sample of 6493 participants (3418 M, 3075 F). 2932 and 3511 participants underwent CEA and CAS respectively. CEA reported a significantly longer mean length of procedure (191.92 vs. 77.5 min, p < 0.0001) and length of stay (3.13 vs. 2.60 days, p < 0.0001) vs. CAS. The mean adjusted cost of CEA and CAS were $18156.60 (6466) and $17711.01 (5511) respectively. Studies reported lower risks of stroke (2.12% vs. 3.65%, p < 0.001), higher risks of myocardial infarctions (1.70% vs. 1.42%, p < 0.01), and higher risks of other complications for CEA vs. CAS respectively. The expected 1-year cost of CEA was marginally lower than CAS ($21264.03 vs. $21433.14, p < 0.05). The cost-effectiveness of CEA was marginally better than CAS (ratio = 1.019, 95% CI [1.017, 1.020)]. Conclusions: CEA provides marginally improved cost-effectiveness over CAS, providing long-term cost benefits to centers with large surgical volumes. However, shorter procedural times and inpatient stays with CAS may improve overall productivity. Cost should hence not be a deciding factor when choosing between CEA and CAS.

30 March 2026 in EP Europace
Verified
Journal Article
Open access
HBHarroop Bola
Harroop Bola
TMThalia Melamed
Thalia Melamed
MAMohamed Allaf
Mohamed Allaf
Joshua J HonJoshua J Hon
Joshua J Hon
GGGayathri Giritharan
Gayathri Giritharan
Fu Siong NgFu Siong Ng
Fu Siong Ng
Aims: Pulmonary vein isolation (PVI) alone achieves modest arrhythmia freedom in persistent atrial fibrillation (PeAF). Ethanol infusion of the vein of Marshall (EIVOM) overcomes heat-sink effects, facilitating mitral isthmus (MI) block, and may represent an effective adjunctive ablation strategy. We aimed to quantify the efficacy and safety of EIVOM through a meta-analysis of randomized controlled trials (RCTs). Methods and results: Systematic review of MEDLINE, Web of Science, and PubMed identified 5 RCTs enrolling 1179 patients (602 EIVOM, 577 control). The primary endpoint was 12-month freedom from any atrial arrhythmia. Random-effects models generated risk ratios (RRs) with 95% confidence intervals (CI). Time-to-event data were pooled using a generic inverse-variance approach to derive hazard ratios (HR). EIVOM-based strategies improved freedom from any arrhythmia (RR 1.16, 95% CI 1.04–1.29; P < 0.001; number needed to treat (NNT) = 10) and from atrial fibrillation (RR 1.11, 95% CI 1.05–1.18; P < 0.001; NNT = 13). Time-to-event analysis demonstrated a sustained reduction in recurrence hazard (HR 0.72, 95% CI 0.64–0.81; P = 0.003; I2 = 0%). Repeat ablation was reduced (RR 0.61; P = 0.009). Fluoroscopy time increased (+9.08 min; P = 0.007), while major complications were comparable (2.5% vs. 2.8%; P = 0.47). Trial sequential analysis confirmed that the cumulative Z-curve crossed the monitoring boundary for benefit for the primary endpoint, indicating that the available evidence is sufficient. Conclusion: In PeAF, EIVOM-based ablation strategies significantly improve 12-month arrhythmia-free survival and reduce repeat procedures without increasing major adverse events. However, the observed benefit reflects composite ablation sets rather than ethanol infusion in isolation, and the predominance of high-volume expert centres may limit generalizability.

15 January 2025 in JACC: Case Reports
Verified
Journal Article
Open access
SESaad M. Ezad
Saad M. Ezad
Joshua J HonJoshua J Hon
Joshua J Hon
DPDivaka Perera
Divaka Perera
KSKalpa De Silva
Kalpa De Silva
A 73-year-old man presented with acute coronary syndrome secondary to stent failure. Intravascular imaging identified a recurrent protruding calcific nodule as the mechanism, which was effectively treated with low-speed rotablation, resulting in ablation of the nodule allowing the application of a drug-coated balloon.

4 September 2024 in JACC: Case Reports
Verified
Journal Article
Open access
Joshua J HonJoshua J Hon
Joshua J Hon

3 February 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Joshua J HonJoshua J Hon
Joshua J Hon
HMHelena Akbarzadeh Mostaghbal
Helena Akbarzadeh Mostaghbal
YAYash Akkara
Yash Akkara
JDJoe M. Das
Joe M. Das